Evidence map›Paper›PMID 40448135›Full record

Trial reportCardiovascular diabetology2025

Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial.

Thomas H Marwick, Amera Halabi, Cheng Hwee Soh, Annie Curtin, Ashleigh-Georgia Sherrif, Atro Azad, Leah Wright

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07770737 (Evaluation of Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07770737 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes: A Multicenter CDM-Based Retrospective Cohort Study With Prospective AI-ECG Validation

Typeobservational_patient_registrySponsorDongtan Sacred Heart HospitalRan2026 to 2027Enrolled100ConditionsType 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases, Stage B Heart Failure
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thomas H Marwick *Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia. tom.marwick@baker.edu.au.
Amera Halabi *Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
Cheng Hwee SohBaker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
Annie CurtinBaker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
Ashleigh-Georgia SherrifBaker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
Atro AzadBaker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.
Leah WrightBaker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, 3004, Australia.

Funding

Astra Zeneca ESR-19-20042
6 · The paper itself

Abstract

backgroundScreening for HF may identify asymptomatic abnormalities of LV structure or function, described as stage B heart failure (SBHF) in asymptomatic patients with type 2 diabetes mellitus (T2DM). Sodium-glucose transport protein-2 (SGLT2) inhibitors are associated with reduction of overt HF in T2DM, but the mechanism of their effect in SBHF remains obscure. We sought to assess the response of cardiac function and exercise capacity to dapagliflozin vs placebo in T2DM with stage B HF.

methodsThe LEAVE-DM (Limiting the progression of Echocardiographically-Assessed left VEntricular dysfunction in Diabetes Mellitus) trial assessed echocardiography and 6-min walk (6MWD) in 262 people with well-controlled T2DM (age 73 ± 7 years; 159 women). Those with LVD (n = 139) were randomized 1:1 to dapagliflozin 10 mg/day or placebo. Follow-up was undertaken at 6 and 24 months and the primary endpoint was global longitudinal strain (GLS).

resultsWithin the randomized group with LV dysfunction, dapagliflozin was associated with reduction of LA volume index (− 2.0 ± 9.0 vs. 0.03 ± 8.6, p = 0.002), and average E/e′ (− 0.1 ± 2.4 vs. 0.7 ± 2.4, p < 0.001), and improved LA reservoir strain (1.8 ± 4.0 vs. − 0.2 ± 4.0, p = 0.02) from baseline to 6 months follow-up. There was an improvement in exercise capacity on dapagliflozin at 6 months follow-up (Δ6MWD 17 ± 46 vs. 2 ± 73 m, p = 0.001). However, although abnormal GLS (< 16%) was less common at 6 months follow-up (41% vs. 49%, p = 0.03), there was no difference in ΔGLS from baseline to 6 months between dapagliflozin and placebo (p = 0.18). There were no significant differences between 6 and 24 months.

conclusionsDapagliflozin showed improvements in diastolic function, atrial function and exercise capacity in in patients with T2DM and SBHF, but no change in GLS. Trial Registration: ACTRN12619001393145 at Australia and New Zealand Clinical Trials registry ( https://www.anzctr.org.au/ ).

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsVentricular Dysfunction, LeftVentricular Function, LeftAgedAged, 80 and overDisease ProgressionDouble-Blind MethodExercise ToleranceFemaleGlobal Longitudinal StrainHumansMaleBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsDapagliflozinDiabetic cardiomyopathyDiastolic dysfunctionSystolic dysfunction

Identifiers

PMID40448135
PMCPMC12125862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.